LITS vs LRMR

Lite Strategy, Inc. vs Larimar Therapeutics, Inc. — Valuation Comparison 2026

LITS

Biotechnology
Lite Strategy, Inc.
Quality
6.5
out of 10
Value Trap
24
SAFE
Price
$1.02
Last close
Models
9/13
Active
VS

LRMR

Biotechnology
Larimar Therapeutics, Inc.
Quality
4.8
out of 10
Value Trap
36
LOW
Price
$3.49
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType LITS Fair ValueLITS Upside LRMR Fair ValueLRMR Upside
Bayesian DCF Intrinsic $0.32 -68.3% $1.86 -46.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.03 -13.2% $1.82 -47.7%
Dynamic NAV Asset-Based $1.81 +77.0% $2.92 -16.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for LITS vs LRMR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LITS vs LRMR — Which Stock Is More Undervalued?

LITS scores higher with a 6.5/10 quality rating vs LRMR's 4.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lite Strategy, Inc. (LITS) and Larimar Therapeutics, Inc. (LRMR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LITS currently trades at $1.02 with a QOC of 6.5/10, while LRMR trades at $3.49 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).